These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 12629773

  • 21. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
    Ghafoori M, Varedi P, Hosseini SJ, Asgari M, Shakiba M.
    Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
    [Abstract] [Full Text] [Related]

  • 22. Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study.
    Gjengstø P, Paus E, Halvorsen OJ, Eide J, Akslen LA, Wentzel-Larsen T, Hoisaeter PA.
    J Urol; 2005 Feb; 173(2):425-8. PubMed ID: 15643193
    [Abstract] [Full Text] [Related]

  • 23. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D.
    Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
    [Abstract] [Full Text] [Related]

  • 24. Alpha 1-antichymotrypsin-PSA (ACT-PSA): a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?
    Reiter W, Stieber P, Schmeller N, Nagel D, Fateh-Moghadam A.
    Anticancer Res; 1997 Aug; 17(6D):4767-70. PubMed ID: 9494604
    [Abstract] [Full Text] [Related]

  • 25. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
    Sözen S, Eskicorapci S, Küpeli B, Irkilata L, Altinel M, Ozer G, Uygur C, Alkibay T, Ozen H.
    Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190
    [Abstract] [Full Text] [Related]

  • 26. [Combined use of PSA density and free to total PSA ratio for cancer detection from patients with PSA elevations].
    Kawai M, Okajima K, Kobayashi K, Moriyama M.
    Hinyokika Kiyo; 2006 Feb; 52(2):113-7. PubMed ID: 16541764
    [Abstract] [Full Text] [Related]

  • 27. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X, Truan D, Alcover J, Quintó L, Molina R, Luque P, Coca F, Ballesta AM.
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [Abstract] [Full Text] [Related]

  • 28. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA, Oguz O, Olgun A, Seçkin B, Ilgan S, Hasimi A, Salih M, Peker F, Kutluay T.
    Ann Clin Lab Sci; 2002 Jun; 32(1):22-30. PubMed ID: 11848613
    [Abstract] [Full Text] [Related]

  • 29. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
    Aksoy Y, Oral A, Aksoy H, Demirel A, Akcay F.
    Ann Clin Lab Sci; 2003 Jun; 33(3):320-3. PubMed ID: 12956448
    [Abstract] [Full Text] [Related]

  • 30. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.
    Miyakubo M, Ito K, Yamamoto T, Takechi H, Ohi M, Suzuki K.
    Int J Urol; 2009 Jun; 16(6):561-5. PubMed ID: 19456991
    [Abstract] [Full Text] [Related]

  • 31. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J, Haese A, Scattoni V, Steuber T, Chun FK, Briganti A, Montorsi F, Graefen M, Huland H, Karakiewicz PI.
    Cancer; 2008 Nov 15; 113(10):2695-703. PubMed ID: 18853417
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, Veltri RW.
    J Urol; 2003 Sep 15; 170(3):723-6. PubMed ID: 12913682
    [Abstract] [Full Text] [Related]

  • 33. [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer].
    Han G, Gao JP, Cao XL, Hong BF, Tang J.
    Zhonghua Wai Ke Za Zhi; 2006 Mar 15; 44(6):379-81. PubMed ID: 16638346
    [Abstract] [Full Text] [Related]

  • 34. PSA density and prostate cancer detection.
    Saema A, Kochakarn W, Lertsithichai P.
    J Med Assoc Thai; 2012 May 15; 95(5):661-6. PubMed ID: 22994025
    [Abstract] [Full Text] [Related]

  • 35. Determination of the relative probability for prostate cancer to avoid unnecessary biopsy.
    Okamura K, Takaba H, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Nagasaka T.
    Int J Urol; 2005 Apr 15; 12(4):346-52. PubMed ID: 15948720
    [Abstract] [Full Text] [Related]

  • 36. [Does plasmatic dilution influence the validity of PSA-tests?].
    Rohde D, Mihelcic V.
    Aktuelle Urol; 2007 Mar 15; 38(2):137-43. PubMed ID: 17390276
    [Abstract] [Full Text] [Related]

  • 37. The use of artificial neural network analysis to improve the predictive accuracy of prostate biopsy in the Japanese population.
    Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A, Arai Y.
    Jpn J Clin Oncol; 2004 Oct 15; 34(10):602-7. PubMed ID: 15591458
    [Abstract] [Full Text] [Related]

  • 38. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Chiang IN, Chang SJ, Pu YS, Huang KH, Yu HJ, Huang CY.
    Urol Int; 2009 Oct 15; 82(3):270-5. PubMed ID: 19440012
    [Abstract] [Full Text] [Related]

  • 39. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
    Romppanen J, Haapalainen T, Punnonen K, Penttilä I.
    Anticancer Res; 2002 Oct 15; 22(1A):415-20. PubMed ID: 12017325
    [Abstract] [Full Text] [Related]

  • 40. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer.
    Mitchell ID, Croal BL, Dickie A, Cohen NP, Ross I.
    J Urol; 2001 May 15; 165(5):1549-53. PubMed ID: 11342915
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.